PRI Drops Suit Against Top Two FCRF Staff; Gilden, Compton Accept “Partnership” Offers
In Brief: Hatch Bill Would Require NDA Sponsors To Pay Fee; IND, Generic Drug NDAs Would Be Exempt
NCI Amends FCRF RFP, Extends Deadline To Nov. 10
Caribbean Conference Reports Incidence Differences With U.S.
Malone Retires As NIH Deputy, Raub To Succeed Him
Eight Win ASCO Young Investigator Awards
Niccotine Reports As Aiding Metastasis
President, Congress, Cancer Letter Take Off
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









